Page 54 - 51 the significance--29.2_opt

References:

1. Koro CE, et al. Antidiabetic medication use and prevalence of chronic kidney
disease among patients with type 2 diabetes mellitus in the United States. Clin.
Therapeutics 2009;31(11):2608-2617.
2. Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of
severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study.
J Clin Endocrinol Metab;95(5):2240-7.
3. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia
1984;27(3):351-7.
4. Haneda M, Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic
subjects with CKD and how? Nephrol Dial Transplant 2009;24(2):338-41.
5. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for
Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49(2 Suppl 2):S12-154.
6. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined
effects of routine blood pressure lowering and intensive glucose control on macro-
vascular and microvascular outcomes in patients with type 2 diabetes: New results
from the ADVANCE trial. Diabetes Care 2009;32(11):2068-74.
7. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, et al.
A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007;30(5):
1049-55.
8. Cavanaugh KL. Diabetes management issues for patients with chronic kidney
disease. Clinical Diabetes 2007;25(3):90-97.
9. Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG. Glycated proteins as indices
of glycaemic control in diabetic patients with chronic renal failure. Diabet Med
1996;13(6):514-9.
10. ADA. Standards of medical care in diabetes. Diabetes Care 2011;34 Suppl 1:S11-61.
11. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measure-
ments in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002;39(2):297-307.
12. Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone
in patients with end-stage renal disease. J Int Med Res 2002;30(4):391-9.
13. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, et al. Glycemic
control is a predictor of survival for diabetic patients on hemodialysis. Diabetes
Care 2001;24(5):909-13.
14. Williams G, Pickup JC. Handbook of Diabetes, 3rd Edition: Wiley-Blackwell, 2004.
15. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
JAMA 2002;287(3):360-72.
16. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in
diabetic patients with end-stage renal disease. Am J Kidney Dis 2000;35(3):500-5.
17. Daiichi Sankyo. Prandin Summary of Product Characteristics. 2009.
®
18. ADA. Executive summary: Standards of medical care in diabetes--2010. Diabetes
Care 2010;33 Suppl 1:S4-10.
®
19. Merck Sharpe & Dohme Ltd. Glucophage Summary of Product Characteristics.
2009.
20. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2
diabetes mellitus. Am J Med 1997;102(1):99-110.
21. Nye HJ, Herrington WG. Metformin: The Safest Hypoglycaemic Agent in Chronic
Kidney Disease? Nephron Clin Pract 2011;118(4):c380-c383.
22. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and
death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71.
23. GlaxoSmithKline. Avandia Summary of Product Characteristics. 2008.
®
24. Takeda. Actos Summary of Product Characteristics. 2007.
25. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment
from bench to bedside. Kidney Int 2006;70(7):1223-33.
26. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmaco-.
kinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin
Pharmacol 2003;43(3):252-9.
27. Mohideen P, Bornemann M, Sugihara J, Genadio V, Sugihara V, Arakaki R. The
metabolic effects of troglitazone in patients with diabetes and end-stage renal
disease. Endocrine 2005;28(2):181-6.

54